Kymera Appoints Jeremy Chadwick, Ph.D., as Chief Operating Officer
Retrieved on:
Monday, May 22, 2023
University, Data management, BS, Senior, Statistics, Simon de Montfort, 6th Earl of Leicester, TPD, Research, Doctor of Philosophy, Sequah Medicine Company, Shire (pharmaceutical company), Patient, Vertex Pharmaceuticals, United Kingdom, Biostatistics, Therapy, Takeda Pharmaceutical Company, Fine chemical, Medical device, Mathematics, Takeda
WATERTOWN, Mass., May 22, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation (TPD) to deliver novel small molecule protein degrader medicines, today announced the appointment of Jeremy Chadwick, Ph.D., as Chief Operating Officer.
Key Points:
- WATERTOWN, Mass., May 22, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation (TPD) to deliver novel small molecule protein degrader medicines, today announced the appointment of Jeremy Chadwick, Ph.D., as Chief Operating Officer.
- Dr. Chadwick joins Kymera with extensive experience overseeing global development operations, regulatory and program management at a range of biopharmaceutical companies.
- As a member of the Company’s senior management team, Dr. Chadwick will develop and execute near-term and long-range strategies to maximize the impact of Kymera’s expanding pipeline.
- He earned his MS and PhD in Statistics from the University of London and a BS in Mathematics from Demontfort University in the United Kingdom.